Jun 26, 2024 04:22 AM
BUSINESS
Novo Nordisk’s Wegovy Approved in China for Weight Loss
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
The diabetes treatment version of the drug, which goes under the brand name Ozempic, was approved in China in April 2021
(Bloomberg) — Novo Nordisk A/S’s blockbuster weight-management drug Wegovy has won approval, opening up competition for next-generation obesity drugs in China.
The National Medical Products Administration gave the nod to Novo to market the weekly jab in China for the treatment of people who are overweight or obese, the Danish company said in a WeChat statement on Tuesday.
You've accessed an article available only to subscribers
VIEW OPTIONS
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- RELATED
Share this article
Open WeChat and scan the QR code
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新